2813-0626

Frontiers in Nephrology

Frontiers Media SA

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 308 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact308 DOIs
2

Add abstracts to 31 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact31 DOIs
3

Deposit reference lists for 9 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact9 DOIs

DOIs for this ISSN

Showing the top 5 of 308 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Editorial: Artificial intelligence in nephrology (10.3389/fneph.2023.1270769)
Abstract References ORCID
58.36 5
2 The role of BAFF and APRIL in IgA nephropathy: pathogenic me… (10.3389/fneph.2023.1346769)
ORCID
46.43 71
3 Central vein stenosis in hemodialysis vascular access: clini… (10.3389/fneph.2023.1280666)
ORCID
42.69 50
4 Pathophysiological concepts and screening of cardiovascular… (10.3389/fneph.2023.1198560)
ORCID
42.03 47
5 Chemotherapy-induced acute kidney injury: epidemiology, path… (10.3389/fneph.2024.1436896)
ORCID
40.32 40
6 Editorial: Social determinants of kidney health: a global pe… (10.3389/fneph.2023.1260221)
Abstract References ORCID
35.78 2
7 Immune checkpoint inhibitor related nephrotoxicity: Advances… (10.3389/fneph.2022.1017921)
ORCID
35.37 25
8 SGLT2 inhibitors in diabetic and non-diabetic kidney transpl… (10.3389/fneph.2024.1332397)
ORCID
35.37 25
9 Charting the future of cardiorenal medicine: a vision for in… (10.3389/fneph.2025.1719673)
Abstract ORCID
34.95 4
10 Insulin and the kidneys: a contemporary view on the molecula… (10.3389/fneph.2023.1133352)
ORCID
33.56 21
11 The roles of heme oxygenase-1 in renal disease (10.3389/fneph.2023.1156346)
ORCID
33.56 21
12 Obesity, Weight Gain, and Fluid Overload in Peritoneal Dialy… (10.3389/fneph.2022.880097)
ORCID
31.97 18
13 IgA nephropathy: a review of existing and emerging therapies (10.3389/fneph.2023.1175088)
ORCID
31.38 17
14 Social, political and legal determinants of kidney health: P… (10.3389/fneph.2022.1024667)
ORCID
30.76 16
15 Therapeutic potential of a novel peripherally restricted CB1… (10.3389/fneph.2023.1138416)
ORCID
30.76 16
16 Clinicopathological differences between Bartonella and other… (10.3389/fneph.2023.1322741)
ORCID
30.76 16
17 The evolution of social media in nephrology education: A min… (10.3389/fneph.2023.1123969)
ORCID
30.10 15
18 Possible benefits for environmental sustainability of combin… (10.3389/fneph.2024.1394200)
Abstract ORCID
30.10 3
19 The evolving panorama of vascular access in the 21st century (10.3389/fneph.2022.917265)
ORCID
29.40 14
20 Cemiplimab for advanced cutaneous squamous cell carcinoma in… (10.3389/fneph.2022.1041819)
ORCID
28.65 13
21 Both hypophosphatemia and hyperphosphatemia are associated w… (10.3389/fneph.2022.935288)
ORCID
28.65 13
22 Sodium First Approach, to Reset Our Mind for Improving Manag… (10.3389/fneph.2022.935388)
ORCID
28.65 13
23 Lupus nephropathy beyond immunosuppression: Searching for ne… (10.3389/fneph.2023.1105676)
ORCID
28.65 13
24 Desidustat: a novel PHD inhibitor for the treatment of CKD-i… (10.3389/fneph.2024.1459425)
ORCID
28.65 13
25 New Insights Into Diuretic Use to Treat Congestion in the IC… (10.3389/fneph.2022.879766)
ORCID
27.85 12
26 Harnessing the Full Potential of Multi-Omic Analyses to Adva… (10.3389/fneph.2022.923068)
ORCID
27.85 12
27 Digital health technology to support care and improve outcom… (10.3389/fneph.2023.1148565)
ORCID
27.85 12
28 NELL1 membranous nephropathy: clinical associations provide… (10.3389/fneph.2024.1323432)
ORCID
27.85 12
29 The road ahead: emerging therapies for primary IgA nephropat… (10.3389/fneph.2025.1545329)
ORCID
27.85 12
30 Machine learning in renal pathology (10.3389/fneph.2022.1007002)
ORCID
26.98 11
31 Primary cilia and actin regulatory pathways in renal ciliopa… (10.3389/fneph.2023.1331847)
ORCID
26.98 11
32 Evidence based treatment for lupus nephritis: present perspe… (10.3389/fneph.2024.1417026)
ORCID
26.98 11
33 The Effect of Statins on Mortality of Patients With Chronic… (10.3389/fneph.2021.821585)
ORCID
26.03 10
34 Acute Kidney Injury and Intestinal Dysbiosis (10.3389/fneph.2022.916151)
ORCID
26.03 10
35 Optimizing peritoneal dialysis catheter placement (10.3389/fneph.2023.1056574)
ORCID
26.03 10
36 Plant-derived compounds for treating autosomal dominant poly… (10.3389/fneph.2023.1071441)
ORCID
26.03 10
37 Systematic review of externally validated machine learning m… (10.3389/fneph.2023.1220214)
ORCID
26.03 10
38 Immune monitoring of allograft status in kidney transplant r… (10.3389/fneph.2023.1293907)
ORCID
26.03 10
39 Temporal trends in hypertension related end stage renal dise… (10.3389/fneph.2023.1339312)
ORCID
26.03 10
40 Pulmonary congestion and systemic congestion in hemodialysis… (10.3389/fneph.2024.1336863)
ORCID
26.03 10
41 Gender and kidney transplantation (10.3389/fneph.2024.1360856)
ORCID
26.03 10
42 SGLT2 inhibitors in the treatment of type 2 cardiorenal synd… (10.3389/fneph.2022.1109321)
ORCID
25.00 9
43 The Burden of Gastrointestinal Complaints in Kidney Transpla… (10.3389/fneph.2022.933954)
ORCID
25.00 9
44 The need for kidney biopsy in the management of side effects… (10.3389/fneph.2023.1043874)
ORCID
25.00 9
45 Treatment of membranous nephropathy: Perspectives on current… (10.3389/fneph.2023.1110355)
ORCID
25.00 9
46 A randomized controlled trial of preemptive rituximab to pre… (10.3389/fneph.2023.1181076)
ORCID
25.00 9
47 Proceedings of a membrane update symposium: advancements, sc… (10.3389/fneph.2024.1455260)
ORCID
25.00 9
48 Continuous Renal Replacement Therapy in Acute Brain Injury (10.3389/fneph.2022.853677)
ORCID
23.86 8
49 The patient safety in extracorporeal blood purification trea… (10.3389/fneph.2022.871480)
ORCID
23.86 8
50 SARS-CoV-2 neutralizing antibody response after three doses… (10.3389/fneph.2022.926635)
ORCID
23.86 8